Lifesci Capital Estimates Upstream Bio Q2 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Stock analysts at Lifesci Capital issued their Q2 2026 EPS estimates for Upstream Bio in a research note issued on Tuesday, March 3rd. Lifesci Capital analyst K. Dellorusso anticipates that the company will post earnings per share of ($0.69) for the quarter. Lifesci Capital currently has a “Outperform” rating and a $43.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. Lifesci Capital also issued estimates for Upstream Bio’s Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($3.05) EPS.

Several other analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Evercore initiated coverage on Upstream Bio in a report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Performance

Shares of NASDAQ:UPB opened at $7.66 on Friday. The firm has a market cap of $413.95 million, a price-to-earnings ratio of -4.07 and a beta of 2.96. The firm has a fifty day moving average price of $21.92 and a 200 day moving average price of $22.29. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.68.

Institutional Investors Weigh In On Upstream Bio

A number of hedge funds have recently bought and sold shares of UPB. GF Fund Management CO. LTD. bought a new position in Upstream Bio during the fourth quarter valued at $29,000. Torren Management LLC bought a new stake in shares of Upstream Bio in the 4th quarter worth about $30,000. Empowered Funds LLC bought a new stake in shares of Upstream Bio in the 4th quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Upstream Bio during the 4th quarter valued at about $71,000. Finally, Russell Investments Group Ltd. raised its position in shares of Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after buying an additional 2,887 shares in the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.